XDx's AlloMap Gets Positive Determination from Aetna

The company said that Aetna has determined that AlloMap is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories